drugset / Trial / NCT07259889
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.
Timeline
- Start
- 2025-06-16
- Primary completion
- 2028-06-15
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEL001 | Cell therapy | 5e+08 cells | Intravenous |
| Subject | CEL001 | Cell therapy | 2e+09 cells | Intravenous |
| Subject | CEL001 | Cell therapy | 5e+09 cells | Intravenous |
Indications
No indication recorded.